Australia · Delayed Price · Currency is AUD Racura Oncology Company Description
Race Oncology Limited operates as a precision oncology company in Australia.
The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial.
It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations.
The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016.
Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
| Country | Australia |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Daniel Tillett |
Contact Details
Address: Gateway, 1 Macquarie Place Sydney, NSW NSW Australia | |
| Phone | 61 2 8051 3043 |
Stock Details
| Ticker Symbol | RAC |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000RAC3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel Tillett | Chief Executive Officer, MD and Director |
| Dr. Peter Michael Smith Ph.D. | Executive Chairman |
| Brendan Brown | Chief Financial Officer |
| Dr. Sophia Moscovis | Vice President of Operations and Strategy |
| Dr. Jose L. Iglesias M.D. | Chief Medical Officer |
| Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary |